Edition:
United States

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

771.00GBp
21 Nov 2017
Change (% chg)

29.00 (+3.91%)
Prev Close
742.00
Open
742.00
Day's High
771.00
Day's Low
736.00
Volume
964,469
Avg. Vol
589,239
52-wk High
779.00
52-wk Low
528.36

Latest Key Developments (Source: Significant Developments)

BTG says CFO Rolf Soderstrom to step down as executive director
Tuesday, 14 Nov 2017 02:00am EST 

Nov 14 (Reuters) - BTG PLC ::THAT AFTER 10 YEARS AS CHIEF FINANCIAL OFFICER (CFO) AT BTG, ROLF SODERSTROM IS TO STEP DOWN AS AN EXECUTIVE DIRECTOR OF COMPANY​.‍INTENDS TO APPOINT DUNCAN KENNEDY TO SUCCEED ROLF AS CFO ON 1 JANUARY 2018​.‍ROLF WILL REMAIN WITH COMPANY UNTIL COMPLETION OF A SMOOTH HANDOVER TO DUNCAN, WHICH IS EXPECTED TO BE CONCLUDED BY 31 MARCH 2018​.  Full Article

BTG H1 ‍adjusted operating profit of 99.1 mln stg vs 78.8 mln stg
Tuesday, 14 Nov 2017 02:00am EST 

Nov 14 (Reuters) - Btg Plc :H1 REVENUE 341.3 MILLION STG.H1 ‍ADJUSTED OPERATING PROFIT OF 99.1 MILLION STG VERSUS 78.8 MILLION STG YEAR AGO​.BTG PLC - ‍FURTHER GROWTH IS EXPECTED IN H2 IN INTERVENTIONAL MEDICINE PRODUCT SALES ​.BTG PLC - ‍PHARMACEUTICALS REVENUES IN H2 WILL REFLECT H1-WEIGHTED SEASONALITY OF CROFAB AND FEWER ANTICIPATED EXPIRY ORDERS FOR DIGIFAB COMPARED WITH H2 2016/17​.‍GROUP'S OVERALL OUTLOOK FOR FULL YEAR TO 31 MARCH 2018 REMAINS UNCHANGED​.  Full Article

BTG Plc reiterates full year product sales guidance
Thursday, 5 Oct 2017 02:00am EDT 

Oct 5 (Reuters) - BTG PLC ::‍GROUP REITERATES ITS PRODUCT SALES GUIDANCE FOR FULL YEAR.‍SPECIALTY PHARMACEUTICALS IS EXPECTED TO GROW BY LOW-TO-MID SINGLE DIGITS AT CER IN FY, WEIGHTED AS EXPECTED TO FIRST HALF.​.‍"DELIVERED A GOOD PERFORMANCE IN FIRST HALF OF YEAR, WITH DOUBLE-DIGIT CER 1 PRODUCT SALES GROWTH"​.CONSIDERING OPTIONS, INCLUDING APPEALING RULING AND LEVEL OF DAMAGES AWARDED REGARDING LITIGATION WITH WELLSTAT THERAPEUTICS CORPORATION​.  Full Article

BTG acquires Roxwood Medical
Thursday, 5 Oct 2017 02:00am EDT 

Oct 5 (Reuters) - BTG Plc :ACQUIRED ROXWOOD MEDICAL, A PROVIDER OF ADVANCED CARDIOVASCULAR SPECIALTY CATHETERS.‍WILL PAY UP TO $80M IN CASH TO ACQUIRE ROXWOOD​.‍TRANSACTION IS EXPECTED TO BE ACCRETIVE TO ADJUSTED EPS FROM SECOND FULL YEAR OF OWNERSHIP​.  Full Article

BTG sees double-digit product sales growth in medium term
Tuesday, 16 May 2017 02:00am EDT 

May 16 (Reuters) - Btg Plc :Fy revenue 570.5 million stg.Are well positioned to capture further value in growing interventional medicine space and to deliver sustained business growth.Adjusted operating profit up 13% at CER in 2016/17.Strong financial position with £155.5m of cash at 31 March 2017.IFRS operating profit and IFRS EPS impacted by previously announced legal settlement (£28.0m).Expect to see product sales at mid-to-high teens percentage growth.Looking beyond 2017/18, we expect to deliver continued double-digit product sales growth.  Full Article

BTG sees FY revenue at or above upper end of guidance range
Thursday, 6 Apr 2017 02:12am EDT 

BTG Plc : Close period update .Revenue is expected to be at or above upper end of guidance range of 535 mln stg - 565 mln stg.  Full Article

BTG reports 24 pct rise in first half revenue to 285.4 mln stg
Tuesday, 15 Nov 2016 02:35am EST 

BTG Plc : Results for half year ended Sept.30 2016 . H1 revenue rose 24 percent to 285.4 mln stg . Says business has performed well during first half, and outlook for full year is strong . Says H1 Specialty Pharmaceuticals revenue was 95.1 mln stg (H1 2015/16: 78.2 mln stg), up 9 pct at CER . Says H1 licensing revenues were 92.2 mln stg (H1 2015/16: 80.9 mln stg), down 1 pct on prior period at CER . Says H1 adjusted operating profit was 78.8 mln stg (H1 2015/16: 62.9 mln stg), up 25 pct at actual exchange rates . Says H1 adjusted basic EPS was 13.9 pence (h1 2015/16: 14.7 pence), down 5 pct on prior period due to lower adjusted profit after tax of 53.4 mln stg (H1 2015/16: 56.4 mln stg) . Says at actual exchange rates, H1 revenue increased by 24 pct to 285.4 mln stg (H1 2015/16: 229.6 mln stg) . Says first half revenues benefited from significant foreign exchange tail winds from weaker sterling .Says reiterate our guidance of strong revenue growth and reflect effect of recent currency movements.  Full Article

BTG's Biocompatibles to settle LC Bead probe for $36 mln
Thursday, 6 Oct 2016 09:29am EDT 

BTG Plc : Settlement of U.S. investigation into LC Bead . Unit Biocompatibles subsidiary reached a settlement with U.S. government in relation to department of justice's investigation of marketing of LC Bead . Says Biocompatibles has agreed to settle all allegations and consequently to pay a total penalty of $36 mln .Investigation focused on period pre-dating BTG's acquisition of Biocompatibles in January 2011.  Full Article

BTG says received approval from Health Canada for DC Bead Lumi
Thursday, 25 Aug 2016 07:00am EDT 

BTG PLC : Says received approval from Health Canada for DC Bead Lumi . Says anticipates securing regulatory clearances for additional radiopaque bead products in other markets worldwide .Says look forward to providing DC Bead Lumi to Canadian physicians during second half of 2016.  Full Article

BTG says pretax profit doubles for FY
Tuesday, 17 May 2016 02:01am EDT 

BTG Plc : FY pretax profit 57.5 million STG versus 26.7 million STG year ago .FY revenue rose 22 percent to 447.5 million STG.  Full Article

BRIEF-BTG says CFO Rolf Soderstrom to step down as executive director

* THAT AFTER 10 YEARS AS CHIEF FINANCIAL OFFICER (CFO) AT BTG, ROLF SODERSTROM IS TO STEP DOWN AS AN EXECUTIVE DIRECTOR OF COMPANY​